LIGAND PHARMACEUTICALS INC
Company Stats
- Market Cap
- $6.2B
- as of Sep 30, 2026
- Shares Outstanding
- 19.9M
- Free Float
- 95.6%
Income Statement
- Revenue
- $268.1M
- Operating Income
- $41.0M
- Net Income
- $124.5M
- EBITDA
- $74.8M
- Revenue Growth, 3Y
- 11.0%
- FCF Margin, 3Y Avg
- 36.8%
- FCF Margin, Worst Year
- 18.2%
Cash Flow
- Free Cash Flow
- $48.9M
- FCF Yield
- 0.8%
- Owner FCF Yield
- 0.0%
Balance Sheet
- Cash & Equivalents
- $174.9M
Returns & Capital
- Share Repurchases
- $15.0M
- Buyback Yield, 3Y Avg
- 0.1%
- SBC, 3Y Avg
- $37.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $268.1M | $48.9M | 18.2% |
| FY2024 | $167.1M | $95.2M | 57.0% |
| FY2023 | $131.3M | $46.1M | 35.1% |
| FY2022 | $196.2M | $119.9M | 61.1% |
| FY2021 | $241.5M | $70.0M | 29.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 8, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 25, 2026
Deals
Ligand to Invest Up to $47 Million in AvenCell
September 23, 2026
Deals
Ligand to Buy Santen's Ryjunea for $23 Million
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 15, 2026
Deals
Ligand Completes $739 Million All-Cash Acquisition of XOMA Royalty
June 22, 2026
Earnings Digest
Bitmine Hits $10.7B Treasury; Booz Allen Expands Defense Tech
Stronger demand supports expansion as pricing diverges
September 25, 2026
Deals
Ligand to Invest Up to $47 Million in AvenCell
September 23, 2026
Deals
Ligand to Buy Santen's Ryjunea for $23 Million
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 15, 2026
Deals
Ligand Completes $739 Million All-Cash Acquisition of XOMA Royalty
June 22, 2026
Earnings Digest
Bitmine Hits $10.7B Treasury; Booz Allen Expands Defense Tech